Topical enviroxime against rhinovirus infection.
AUTOR(ES)
Levandowski, R A
RESUMO
Enviroxime, an inhibitor of rhinovirus replication, was studied in a double-blind, placebo-controlled trial with 99 volunteers. The efficacy of a nasal-spray formulation of enviroxime was tested as pretreatment or as postchallenge treatment for rhinovirus type 4 infection. In the regimens used, drug administration neither prevented infection nor reduced the frequency of specific colds. The mean concentration of enviroxime in nasal washes (12 h after a dose) differentiated two groups of responders. Those in whom the drug concentration exceeded 100 ng/ml had some benefits, although these were statistically insignificant.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=185710Documentos Relacionados
- Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection.
- Therapeutic activity of enviroxime against rhinovirus infection in volunteers.
- Controlled trial of enviroxime against natural rhinovirus infections in a community.
- Ipratropium bromide treatment of experimental rhinovirus infection.
- Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.